Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Centessa Pharmaceuticals Plc's Business Segments
Centessa Pharmaceuticals Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 15
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Reportable100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 15 | 100% |
Description of Centessa Pharmaceuticals Plc
Centessa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company that is focused on developing transformative medicines for patients who have unmet medical needs. They are committed to bridging the gap between science and patients, and they are working hard to develop therapies that can change the course of disease.
The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. Centessa is a publicly traded company on the NASDAQ stock exchange and is traded under the symbol CNTA. They have a diverse pipeline of drug candidates that are focused on a variety of therapeutic indications, including immuno-oncology, hematology, and genetic diseases.
One of the hallmarks of Centessa is its unique business model, which is based on a "hub-and-spoke" approach. They have acquired a number of smaller biotech companies and are operating them as individual subsidiaries, each with its own research and development team. This allows Centessa to harness the power of multiple organizations and bring together a range of expertise and resources.
The company's pipeline includes a number of promising drug candidates, including CNV1014802, which is being developed for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disorder that causes the formation of bone in soft tissue. They also have several immuno-oncology candidates, including CMP-001, a toll-like receptor agonist that is being developed in conjunction with Tecentriq for the treatment of multiple types of cancer.
In addition to its pipeline, Centessa is also actively pursuing partnerships and collaborations with other companies and organizations in order to expand its reach and accelerate the development of its drug candidates. They are committed to developing innovative and effective therapies for patients in need, and they are rapidly becoming a major player in the biopharmaceutical industry.
The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. Centessa is a publicly traded company on the NASDAQ stock exchange and is traded under the symbol CNTA. They have a diverse pipeline of drug candidates that are focused on a variety of therapeutic indications, including immuno-oncology, hematology, and genetic diseases.
One of the hallmarks of Centessa is its unique business model, which is based on a "hub-and-spoke" approach. They have acquired a number of smaller biotech companies and are operating them as individual subsidiaries, each with its own research and development team. This allows Centessa to harness the power of multiple organizations and bring together a range of expertise and resources.
The company's pipeline includes a number of promising drug candidates, including CNV1014802, which is being developed for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disorder that causes the formation of bone in soft tissue. They also have several immuno-oncology candidates, including CMP-001, a toll-like receptor agonist that is being developed in conjunction with Tecentriq for the treatment of multiple types of cancer.
In addition to its pipeline, Centessa is also actively pursuing partnerships and collaborations with other companies and organizations in order to expand its reach and accelerate the development of its drug candidates. They are committed to developing innovative and effective therapies for patients in need, and they are rapidly becoming a major player in the biopharmaceutical industry.
Centessa Pharmaceuticals Plc is a dynamic and innovative pharmaceutical company dedicated to developing and commercializing transformative medicines aimed at addressing significant unmet medical needs across various therapeutic areas. The companys portfolio spans critical segments, each with its own focus on advancing therapeutics that promise to improve patient outcomes. Below is an extensive overview of the segments, products, and services offered by Centessa Pharmaceuticals.
Segments
1. Oncology
Centessas oncology segment is at the forefront of developing cutting-edge therapies for cancer treatment. This segment is dedicated to creating innovative solutions for various malignancies, particularly focusing on:
- Ovarian Cancer: Therapeutics aimed at improving survival rates and enhancing quality of life for patients diagnosed with ovarian cancer.
- Breast Cancer: Development of targeted therapies that focus on specific cancer markers to personalize treatment for different breast cancer subtypes.
- Solid Tumor Malignancies: Advanced research into treatments for a variety of solid tumors, harnessing novel mechanisms of action to target cancer cells effectively.
2. Immunology/Inflammation
The immunology/inflammation segment emphasizes developing therapeutics that specifically target inflammatory pathways. This area encompasses:
- Inflammatory Bowel Disease (IBD): Focused on therapies that provide relief from symptoms and promote remission in patients suffering from IBD.
- Rheumatoid Arthritis: Development of systemic treatments aimed at controlling disease activity and minimizing joint damage.
- Psoriasis and Autoimmune Disorders: Exploration of targeted therapies that mitigate symptoms and alter disease progression in autoimmune conditions.
3. Rare Diseases
Centessa is committed to addressing the needs of patients with rare and genetic disorders, an often underserved area in pharmaceuticals. Key focuses include:
- Hereditary Angioedema: Therapeutics designed to manage episodes and provide long-term control for patients with this genetic condition.
- Duchenne Muscular Dystrophy (DMD): Researching and developing treatments that aim to slow the progression of this debilitating muscular disorder.
- Fabry Disease: Advancing therapies for this lysosomal storage disorder to alleviate symptoms and prevent complications associated with the disease.
Products
1. Onivodulimab
- Description: A monoclonal antibody treatment primarily developed for addressing inflammatory bowel disease, targeting specific pathways involved in the inflammatory response.
- Indication: Aims to reduce inflammation and promote healing in the gastrointestinal tract.
2. Cerdulatinib
- Description: This dual inhibitor specifically targets Brutons tyrosine kinase (BTK) and Janus kinase (JAK), making it a powerful option for the treatment of lymphoma and other hematologic malignancies.
- Indication: Facilitates effective management of various blood cancers, enhancing patient outcomes.
3. CNP-101/TAK-659
- Description: A selective spleen tyrosine kinase (SYK) inhibitor demonstrated to possess efficacy in managing rheumatoid arthritis and other autoimmune diseases.
- Indication: Provides an innovative approach to modulating immune responses, particularly in autoimmune pathology.
4. ETX0282CPDP
- Description: A beta-lactamase inhibitor designed to combat antibiotic resistance, especially in infections caused by Gram-negative bacteria.
- Indication: Aims to restore the efficacy of beta-lactam antibiotics against resistant strains.
Services
1. Clinical Trials
- Overview: Centessa is deeply involved in conducting rigorous clinical trials to assess the safety, tolerability, and efficacy of its therapeutics. These trials are crucial for moving drug candidates through the development pipeline and into clinical practice.
2. Scientific Advisory
- Overview: Centessa provides expert scientific advisory services aimed at guiding partners through clinical development plans, drug discovery processes, and translational research efforts. These services ensure that the development strategy is grounded in the latest scientific insights.
3. Regulatory Strategy
- Overview: The company offers regulatory strategy consulting to facilitate the approval processes for both in-house developed and in-licensed drug candidates. This includes navigating complex regulatory frameworks to achieve timely market entry for their innovative products.
Conclusion
Through its focused segments, innovative product pipeline, and strategic services, Centessa Pharmaceuticals Plc is making significant strides in the healthcare industry. By prioritizing the development of transformative therapies for conditions with unmet medical needs, the company is committed to enhancing patient care and improving health outcomes worldwide.
Segments
1. Oncology
Centessas oncology segment is at the forefront of developing cutting-edge therapies for cancer treatment. This segment is dedicated to creating innovative solutions for various malignancies, particularly focusing on:
- Ovarian Cancer: Therapeutics aimed at improving survival rates and enhancing quality of life for patients diagnosed with ovarian cancer.
- Breast Cancer: Development of targeted therapies that focus on specific cancer markers to personalize treatment for different breast cancer subtypes.
- Solid Tumor Malignancies: Advanced research into treatments for a variety of solid tumors, harnessing novel mechanisms of action to target cancer cells effectively.
2. Immunology/Inflammation
The immunology/inflammation segment emphasizes developing therapeutics that specifically target inflammatory pathways. This area encompasses:
- Inflammatory Bowel Disease (IBD): Focused on therapies that provide relief from symptoms and promote remission in patients suffering from IBD.
- Rheumatoid Arthritis: Development of systemic treatments aimed at controlling disease activity and minimizing joint damage.
- Psoriasis and Autoimmune Disorders: Exploration of targeted therapies that mitigate symptoms and alter disease progression in autoimmune conditions.
3. Rare Diseases
Centessa is committed to addressing the needs of patients with rare and genetic disorders, an often underserved area in pharmaceuticals. Key focuses include:
- Hereditary Angioedema: Therapeutics designed to manage episodes and provide long-term control for patients with this genetic condition.
- Duchenne Muscular Dystrophy (DMD): Researching and developing treatments that aim to slow the progression of this debilitating muscular disorder.
- Fabry Disease: Advancing therapies for this lysosomal storage disorder to alleviate symptoms and prevent complications associated with the disease.
Products
1. Onivodulimab
- Description: A monoclonal antibody treatment primarily developed for addressing inflammatory bowel disease, targeting specific pathways involved in the inflammatory response.
- Indication: Aims to reduce inflammation and promote healing in the gastrointestinal tract.
2. Cerdulatinib
- Description: This dual inhibitor specifically targets Brutons tyrosine kinase (BTK) and Janus kinase (JAK), making it a powerful option for the treatment of lymphoma and other hematologic malignancies.
- Indication: Facilitates effective management of various blood cancers, enhancing patient outcomes.
3. CNP-101/TAK-659
- Description: A selective spleen tyrosine kinase (SYK) inhibitor demonstrated to possess efficacy in managing rheumatoid arthritis and other autoimmune diseases.
- Indication: Provides an innovative approach to modulating immune responses, particularly in autoimmune pathology.
4. ETX0282CPDP
- Description: A beta-lactamase inhibitor designed to combat antibiotic resistance, especially in infections caused by Gram-negative bacteria.
- Indication: Aims to restore the efficacy of beta-lactam antibiotics against resistant strains.
Services
1. Clinical Trials
- Overview: Centessa is deeply involved in conducting rigorous clinical trials to assess the safety, tolerability, and efficacy of its therapeutics. These trials are crucial for moving drug candidates through the development pipeline and into clinical practice.
2. Scientific Advisory
- Overview: Centessa provides expert scientific advisory services aimed at guiding partners through clinical development plans, drug discovery processes, and translational research efforts. These services ensure that the development strategy is grounded in the latest scientific insights.
3. Regulatory Strategy
- Overview: The company offers regulatory strategy consulting to facilitate the approval processes for both in-house developed and in-licensed drug candidates. This includes navigating complex regulatory frameworks to achieve timely market entry for their innovative products.
Conclusion
Through its focused segments, innovative product pipeline, and strategic services, Centessa Pharmaceuticals Plc is making significant strides in the healthcare industry. By prioritizing the development of transformative therapies for conditions with unmet medical needs, the company is committed to enhancing patient care and improving health outcomes worldwide.